Investee Company Update: Little Green Pharma Ltd

SEED Innovations Ltd, the AIM-quoted investment company offering exposure to disruptive, high-growth, life sciences and technology ventures typically inaccessible to everyday investors, is pleased to note that its portfolio company, Little Green Pharma Ltd ('LGP'), has published its quarterly activities report and Appendix 4C for the period ending 31 March 2025 on the ASX.

The Company owns 7,324,796 ordinary shares in LGP representing 2.43% of LGP's issued share capital.

Commenting on the announcement, Ed McDermott, SEED CEO, said: "LGP continues to deliver strong double-digit year-on-year growth, with cash receipts surpassing A$10 million in the quarter ended 31 March 2025. The company remains in a solid financial position, with net tangible assets significantly outweighing its enterprise value and minimal long-term debt. Increasing sales momentum in Germany and the UK further reinforces LGP's strategic direction, and we remain confident in the company's ability to sustain this positive trajectory."

Little Green Pharma Ltd

Quarterly Activities Report and Appendix 4C

Little Green Pharma Ltd (ASX: LGP, "LGP" or the "Company") is pleased to provide its activities report and Appendix 4C for the quarter ending 31 March 2025.

Highlights

• LGP FY25 revenue of $36.6 million (unaudited) representing over 40% growth from prior year, with Health House generating further $0.8 million in third party product sales in two months post-acquisition
• LGP revenue of $9.6 million (unaudited) for quarter, up over 30% from prior corresponding period with record March month of $4.0 million (unaudited)
• Cash receipts including Health House of $10.3 million up nearly 30% from prior corresponding period
• Successful acquisition and integration of Health House distribution business
• NAB loan facilities extended to 30 June 2027
• French national cannabis legislation submitted to European Commission; commercial access expected late CY25 / early CY26
• 12-month QUEST results released and published in PLOS One journal with results showing long-term efficacy of LGP medicinal cannabis for various chronic conditions
• Department of Veterans Affairs confirmed funding of MDMA and Psilocybin assisted therapies for veterans with post-traumatic stress disorder and treatment resistant depression
• Strengthening of board with appointment of Mr Paul Long as Managing Director and Mr David Fenlon as an Independent Non Executive Director
• Cash in bank of $2.4 million

The announcement in full can be accessed from the following link: https://www.investlittlegreenpharma.com/site/showdownloaddoc.aspx?AnnounceGuid=715a80ae-ca84-4a24-9aff-d8791e2321c4

Nominated Adviser